Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ZYUS Life SciencesZLSCF 3-Year Share Buyback Ratio is -4.70 as of Mar. 2026. The stock has 7 warning signs investors should review. Among 647 Drug Manufacturers companies, ZYUS Life Sciences ranks worse than 60.59% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. ZYUS Life Sciences's current 3-Year Share Buyback Ratio was -4.70%.
The historical rank and industry rank for ZYUS Life Sciences's 3-Year Share Buyback Ratio or its related term are showing as below:
ZLSCF'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -4.7 Med: -3.4 Max: -2.1
Current: -4.7
During the past 5 years, ZYUS Life Sciences's highest 3-Year Share Buyback Ratio was -2.10%. The lowest was -4.70%. And the median was -3.40%.
ZLSCF's 3-Year Share Buyback Ratio is ranked worse than 60.59% of 647
companies
in the Drug Manufacturers industry
Industry Median: -1.9
vs ZLSCF: -4.70
ZYUS Life Sciences (OTCPK:ZLSCF) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
ZYUS Life Sciences 3-Year Share Buyback Ratio Related Terms
ZLSCF vs RMTI, BTAI, MRMD: 3-Year Share Buyback Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ZYUS Life Sciences's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ZYUS Life Sciences 3-Year Share Buyback Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ZYUS Life Sciences's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where ZYUS Life Sciences's 3-Year Share Buyback Ratio falls into.
ZYUS Life Sciences 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -4.70 mean?
ZYUS Life Sciences (ZLSCF) has a 3-Year Share Buyback Ratio of -4.70 as of Mar. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for ZYUS Life Sciences and its competitors. According to the industry distribution chart, ZYUS Life Sciences ranks #392 out of 647 companies in the Drug Manufacturers industry, placing it in the top 60.6%.
Is ZYUS Life Sciences' 3-Year Share Buyback Ratio too high?
ZYUS Life Sciences' current 3-Year Share Buyback Ratio is -4.70. Based on the distribution chart, ZYUS Life Sciences ranks #392 out of 647 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does ZYUS Life Sciences' 3-Year Share Buyback Ratio compare to RMTI and BTAI?
According to the Drug Manufacturers industry distribution chart, ZYUS Life Sciences ranks #392 out of 647 companies for 3-Year Share Buyback Ratio. This places ZYUS Life Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Drug Manufacturers company?
A good 3-Year Share Buyback Ratio depends on the Drug Manufacturers industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for ZYUS Life Sciences and its competitors. ZYUS Life Sciences's current 3-Year Share Buyback Ratio is -4.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ZYUS Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, ZYUS Life Sciences (ZLSCF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.60, compared to a current price of $0.01 — trading 97.7% below its estimated fair value. The current 3-Year Share Buyback Ratio is -4.70. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For ZYUS Life Sciences (ZLSCF), the current 3-Year Share Buyback Ratio is -4.70 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ZYUS Life Sciences Corp is primarily engaged in the world-wide development and commercialization of cannabinoid-based therapeutics and product candidates. It is a licensed producer and distributor of medical cannabis for both medical and adult recreational access in Canada. The company has one reportable segment: Bio-pharmaceutical Products (including medical cannabis derivatives). Geographically, it operates in Canada; United States; Australia; and European Union.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLSCF has been successfully added to your 
